RSS
2 Dec 2021

Orexo develops a nasal adrenaline medication based on the novel amorphOXTM platform

Author: admintech | Filed under: Press Release

UPPSALA, Sweden, Dec. 2, 2021 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces it has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Adrenaline is commonly used for the…

This entry was posted on Thursday, December 2nd, 2021 at 2:24 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»